NEW YORK--(BUSINESS WIRE)--Click Therapeutics today announced the execution of a new collaboration agreement with Indivior for the development and commercialization of prescription digital therapeutics to treat substance use disorders, beginning with Opioid Use Disorder (OUD). Through a novel mobile application, CT-102, the collaboration aims to help close major gaps in OUD treatment, such as access to high-quality, personalized psychosocial treatment.
Designed to work alongside pharmacotherapy, CT-102 will combine evidence-based behavioral therapy with tailored neuromodulatory interventions using Click’s AI-enabled platform to deliver personalized care to each patient. This collaboration will build on Indivior’s expertise in the commercialization of innovative treatments for substance use disorders and Click Therapeutics’ substantial real-world experience engaging patients seeking help with addiction.
Click will lead development with an iterative, patient-centric and evidence-based approach that leverages the company’s end-to-end development capabilities and proprietary technology platform. This phased process is designed to ensure CT-102 will be launched as a best-in-class therapy supported by compelling evidence that will drive broad access and adoption. These efforts will start with a preliminary exploration phase to explore and define the product scope that will best match the needs of patients, providers and payers. More information will be available following completion of the exploration phase in 2024.
This is the fourth major co-development and commercialization collaboration to be announced that is based on Click Therapeutics’ clinically validated platform. Under the terms of the collaboration agreement, Click Therapeutics will be responsible for all technical and clinical development activities, as well as regulatory filings and technical services through commercialization. In return, Indivior will receive a global license to commercialize CT-102. Click Therapeutics will receive upfront license and early development payments, and is eligible to receive additional regulatory and commercial milestones plus double-digit royalties on global sales. In addition, there is an opportunity for a higher total deal value based on the potential development of additional products in the future.
About Click Therapeutics
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. Click Therapeutics continuously expands and refines its platform with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. The digital therapeutics under development on Click’s platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. Consistently named a best place to work, Click fosters an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in a common mission to provide patients everywhere access to safe and effective prescription digital therapeutics.
For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn.
